Recombinant Cynomolgus BLAME/SLAMF8 His-tag Protein, CF

Recombinant Cynomolgus Monkey BLAME/SLAMF8 His-tag (Catalog # 11395-BL) binds Biotinylated Recombinant Cynomolgus Monkey BLAME/SLAMF8 Fc Chimera with an ED50 of 60.0-720 ng/mL.

2 μg/lane of Recombinant Cynomolgus Monkey BLAME/SLAMF8 His-tag Protein (Catalog # 11395-BL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 31-39 kDa, under reducing conditions.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus BLAME/SLAMF8 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. Recombinant Cynomolgus Monkey BLAME/SLAMF8 His-tag (Catalog # 11395-BL) binds Biotinylated Recombinant Cynomolgus Monkey BLAME/SLAMF8 Fc Chimera with an ED₅₀ of 60.0-720 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived cynomolgus monkey BLAME/SLAMF8 protein
  Ala23-Asp233, with a C-terminal 6-His tag
• Accession #: XP_005541356.1
• N-terminal Sequence: Ala23
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 24 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 31-39 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus BLAME/SLAMF8 His-tag Protein, CF

• B Lymphocyte Activator Macrophage Expressed
• BCM-Like Membrane Protein
• BLAME
• B-Lymphocyte Activator Macrophage Expressed
• CD353 Antigen
• CD353
• SBBI42
• SLAM Family Member 8
• SLAMF8

Background

B-lymphocyte activator macrophage expressed (BLAME), also known as SLAMF8, is a type I transmembrane protein that belongs to the CD2 subset of immunoglobulin superfamily cell receptors. The SLAM family is comprised of nine surface receptors, expressed mainly on hematopoietic cells, and they have been shown to function as adhesion molecules and modulators of immune responses (1). BLAME, along with SLAMF2 and SLAMF9, are considered atypical SLAM family members due to the low homology in their cytoplasmic domains compared to the rest of the SLAM family (2). Mature cynomologus BLAME consists of an extracellular domain (ECD) with an IgV and an IgC2 domain, a transmembrane segment, and a short cytoplasmic domain. Within the ECD, cynomologus BLAME shares 96% amino acid sequence identity with human BLAME. BLAME is expressed by various myeloid cells, such as neutrophils, macrophages, and dendritic cells (3). BLAME suppresses macrophage function but enhances the growth of neoplastic mast cells via SHP-2 (4). BLAME negatively regulates the activity of PKC-δ, which phosphorylates the p40phox subunit of the NOX2 complex (5). BLAME is abundantly expressed in T cells in pediatric cancers and Epstein-Barr virus-positive gastric cancers and is a potential immunotherapy target for several diseases (6-8). Higher SLAMF8 expression may predict better anti-PD1 immunotherapy efficacy in GI cancer (9).

1. Shachar, I. et al. (2019) Clin. Immunol. 204:23.
2. Dragovich, M.A. and Mor, A. (2018) Autoimmunity reviews, 17:674.
3. Wang, G. et al. (2015) PloS one, 10:e0121968.
4. Sugimoto, A. et al. (2018) Exp. Dermatol. 27:641.
5. Wang, G. et al. (2012) J. Immunol. 188:5829.
6. Orentas, R.J. et al. (2012) Front Oncol. 2:194.
7. Sugimoto, A. et al. (2020) Sci. Rep. 10:2505.
8. Zhang, Q. et al. (2019) J. Clin. Oncol. 37:e14078.
9. Zhang Q. et al. (2021) Clin. Transl. Immunology. 10:1347.

Bioinformatics

• Uniprot:
  • XP_005541356.1()